Concurrent palliative radiation with pembrolizumab for platinum-refractory urothelial carcinoma is associated with improved overall survival

von der Maase, 2000, Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study, J Clin Oncol, 18, 3068, 10.1200/JCO.2000.18.17.3068 Bellmunt, 2017, Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma, N Engl J Med, 376, 1015, 10.1056/NEJMoa1613683 Uchimoto, 2021, Risk Classification for Overall Survival by the Neutrophil-Lymphocyte Ratio and the Number of Metastatic Sites in Patients Treated with Pembrolizumab-A Multicenter Collaborative Study in Japan, Cancers (Basel), 13, 3554, 10.3390/cancers13143554 Kobayashi, 2021, Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab, Cancer Sci, 112, 760, 10.1111/cas.14762 Deng, 2014, Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice, J Clin Invest, 124, 687, 10.1172/JCI67313 Zeng, 2013, Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas, Int J Radiat Oncol Biol Phys, 86, 343, 10.1016/j.ijrobp.2012.12.025 Dovedi, 2014, Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade, Cancer Res, 74, 5458, 10.1158/0008-5472.CAN-14-1258 Rompre-Brodeur, 2020, PD-1/PD-L1 immune checkpoint inhibition with radiation in bladder cancer: in situ and abscopal effects, Mol Cancer Ther, 19, 211, 10.1158/1535-7163.MCT-18-0986 Kim, 2021, Abscopal effect after palliative five-fraction radiation therapy on bone and lymph node metastases from luminal B breast cancer: a case report and clinical implications for palliative radiation therapy, Radiat Oncol J, 39, 139, 10.3857/roj.2020.00990 Ribeiro Gomes, 2016, Analysis of the Abscopal Effect With Anti-PD1 Therapy in Patients With Metastatic Solid Tumors, J Immunother, 39, 367, 10.1097/CJI.0000000000000141 Trommer, 2019, Abscopal effects in radio-immunotherapy-response analysis of metastatic cancer patients with progressive disease under anti-PD-1 immune checkpoint inhibition, Front Pharmacol, 10, 10.3389/fphar.2019.00511 Daro-Faye, 2021, Combined radiotherapy and immunotherapy in urothelial bladder cancer: harnessing the full potential of the anti-tumor immune response, World J Urol, 39, 1331, 10.1007/s00345-020-03440-4 Lala, 2020, A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation, Eur J Cancer, 131, 68, 10.1016/j.ejca.2020.02.016 Seymour, 2017, iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics, Lancet Oncol, 18, e143, 10.1016/S1470-2045(17)30074-8 Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026 Fradet, 2019, Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up, Ann Oncol, 30, 970, 10.1093/annonc/mdz127 Abuodeh, 2016, Systematic review of case reports on the abscopal effect, Curr Probl Cancer, 40, 25, 10.1016/j.currproblcancer.2015.10.001 Grassberger, 2019, Assessing the interactions between radiotherapy and antitumour immunity, Nat Rev Clin Oncol, 16, 729, 10.1038/s41571-019-0238-9 Reits, 2006, Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy, J Exp Med, 203, 1259, 10.1084/jem.20052494 Yarchoan, 2017, Targeting neoantigens to augment antitumour immunity, Nat Rev Cancer, 17, 209, 10.1038/nrc.2016.154 Zhao, 2020, Radiotherapy-mediated immunomodulation and anti-tumor abscopal effect combining immune checkpoint blockade, Cancers (Basel), 12, 2762, 10.3390/cancers12102762 Gong, 2018, Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination, J Immunother Cancer, 6, 46, 10.1186/s40425-018-0361-7 Sundahl, 2019, Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma, Eur Urol, 75, 707, 10.1016/j.eururo.2019.01.009 Komura, 2021, Increased BUB1B/BUBR1 expression contributes to aberrant DNA repair activity leading to resistance to DNA-damaging agents, Oncogene, 40, 6210, 10.1038/s41388-021-02021-y Nishimura, 2022, Efficacy of pembrolizumab and comprehensive CD274/PD-L1 profiles in patients previously treated with chemoradiation therapy as radical treatment in bladder cancer, J Immunother Cancer, 10, e003868, 10.1136/jitc-2021-003868 Powles, 2020, Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma, N Engl J Med, 383, 1218, 10.1056/NEJMoa2002788 Uchimoto, 2022, Re-challenging chemotherapy after pembrolizumab in platinum-refractory urothelial carcinoma, BJU Int, 10.1111/bju.15893 Szabados, 2018, Response rate to chemotherapy after immune checkpoint inhibition in metastatic urothelial cancer, Eur Urol, 73, 149, 10.1016/j.eururo.2017.08.022